Further research may lead to the discovery of biomarkers for early detection of leukemic progression, promoting a deeper understanding of molecular mechanisms by which RUNX1 mutations contribute to hematological malignancies and the development of new therapeutic interventions. The gene discussed is RUNX1; the disease is hematologic disorder.